- $24.39bn
- $20.57bn
- $5.14bn
Brief: Knight Therapeutics Announces Regulatory Supplemental Submission Of Minjuvi® (Tafasitamab) For Follicular Lymphoma In Argentina And Mexico
Brief: Knight Therapeutics Announces Approval Of Additional Indication For Minjuvi® (Tafasitamab) In Brazil
U.S. RESEARCH ROUNDUP- Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
Brief: Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing
Brief: Incyte Announces The European Commission Approval Of Zynyz® (retifanlimab) For The First-Line Treatment Of Advanced Squamous Cell Carcinoma Of The Anal Canal (SCAC)
Pharma companies left out of Trump's drug-pricing deals look for way in
U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart
U.S. STOCKS ON THE MOVE-Target, Warner Bros Discovery , Copper miners
U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab
U.S. STOCKS ON THE MOVE-Vistra Corp, Quest Diagnostics, Jacobs Solutions
Drugmaker Incyte falls after downbeat annual revenue forecast
Incyte weak 2026 revenue forecast heightens Jakafi patent concerns
Incyte Q4 revenue growth beats estimates on demand for Jakafi
Prelude Therapeutics rises after FDA clears early-stage trial of blood cancer drug
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
U.S. RESEARCH ROUNDUP-Cencora, Kennametal, Regeneron Pharmaceuticals
U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group
U.S. STOCKS ON THE MOVE-Qualcomm, Costco, Topgolf Callaway Brands
Brief: Incyte Announces Positive Topline Results From Study Of Tafasitamab